Drug Testing Locations in Washington

Accredited Drug Testing has 260 drug testing centers in 1,039 WA cities.

Please select a city from the list below to find drug test centers in Washington.

Why Washington Employers Should Choose Our Drug Testing Services

Employers across Washington should leverage our drug testing services to foster a safer and more productive workplace. With 260 centers in 1,039 cities, access is streamlined for both employees and employers alike.

Drug testing helps mitigate risks associated with workplace substance abuse, such as accidents and lowered productivity. Our comprehensive testing services ensure you have the data necessary to maintain a safe work environment.

Additionally, implementing regular drug testing helps uphold your company’s reputation and regulatory compliance, adhering to state and federal guidelines.

Choose our services to create a culture of accountability and safety. Testing programs can be customized to meet specific organizational needs, ensuring flexibility and reliability.

Our experienced staff and cutting-edge technology guarantee accurate and confidential results, offering peace of mind to employers regardless of their industry or size.

Washington Drug Free Workplace Programs

Washington demonstrates a strong commitment to fostering a healthy work environment through its initiatives that promote safety and productivity. Though it does not have a formal "Drug Free Workplace Program," the state emphasizes practices that mitigate substance abuse in professional settings. This proactive stance includes providing resources and support for employers to address substance misuse and create safer working conditions.

One of the critical components of Washington's approach is the collaboration between state agencies and businesses to raise awareness about the impacts of substance abuse. Employers are encouraged to adopt policies that not only deter drug use but also support employees through education and access to assistance programs. By focusing on these proactive measures, Washington aims to enhance workplace safety and employee well-being, ultimately contributing to a more prosperous state economy.

How does the body eliminate Drugs

Drug elimination is the sum of the processes of removing an administered drug from the body. In the pharmacokinetic ADME scheme (absorption, distribution, metabolism, and excretion), it is frequently considered to encompass both metabolism and excretion. Hydrophobic drugs, to be excreted, must undergo metabolic modification making them more polar. Hydrophilic drugs, on the other hand, can undergo excretion directly, without the need for metabolic changes to their molecular structures.

Although many sites of metabolism and excretion exist, the chief organ of metabolism is the liver, while the organ primarily tasked with excretion is the kidney. Any significant dysfunction in either organ can result in the accumulation of the drug or its metabolites in toxic concentrations.

A variety of other factors impact elimination — intrinsic drug properties, such as polarity, size, or pKa. Also other factors include genetic variation among individuals, disease states affecting other organs, and pathways involved in the way the drug distributes through the body, such as first-pass metabolism.

Issues of Concern

Drug elimination is the removal of an administered drug from the body. It is accomplished in two ways, either by excretion of an unmetabolized drug in its intact form or by metabolic biotransformation followed by excretion. While excretion is primarily carried out by the kidneys, other organ systems are involved as well. Similarly, the liver is the primary site of biotransformation, yet extrahepatic metabolism takes place in a variety of organ systems affecting multiple drugs.

Given the multiple organ systems and the variety of metabolic transformations present, drug elimination can entail a significant degree of complexity. Hydrophilic drugs are typically directly excreted by the kidneys, while hydrophobic drugs undergo biotransformation before excretion. The purpose here is twofold – biotransformation serves both detoxify the exogenous substances as well as to increase their hydrophilicity, ensuring their elimination via the kidneys.

Two broad metabolic pathways of hepatic drug transformation exist. Phase I is the direct modification of the target molecule, whereas phase II entails conjugation of the target to a polar molecule of low molecular weight. Phase I prepare the drug to enter phase II, but single-phase metabolism also exists.

Phase I involves oxidation, reduction, and hydrolysis of the exogenous molecule. These reactions are accomplished by hepatic microsomal enzymes, which reside in the smooth endoplasmic reticulum of the hepatocytes. Best known among them is the cytochrome P450 system, whose enzymes are predominantly involved in oxidative metabolism. Within the cytochrome P450 family (CYP), the enzyme responsible for the metabolism of more than 50% of existing drugs is the CYP3A4. Its activity encompasses various classes of medications, including opioids, immunosuppressants, antihistamines, and benzodiazepines. The enzymes can also be induced or inhibited by a variety of substances they interact with, including pharmaceuticals. The increase in metabolic activity with CYP induction results in a diminished activity of drugs targeted by that particular isoform. Conversely, CYP inhibition will result in increased drug plasma concentration, potentially leading toxicity. The CYP3A4 is induced by phenytoin, phenobarbital, and St. John's wort, while diltiazem, erythromycin, and grapefruit inhibit it. Caution is, therefore, necessary when administering CYP3A4-metabolized drugs in the presence of any of the inhibitors or inducers.

Phase II consists of covalent bonding of polar groups to nonpolar molecules to render them water-soluble and allow renal or biliary excretion. Target molecules enter phase II directly or via initial processing through phase I. A variety of polar adjuncts is transferred, including amino acids, glucuronic acid, glutathione, acetate, and sulfate. Glucuronidation is one of the major pathways of phase II biotransformation. The UDP-glucuronosyltransferase (UGT) enzyme family performs this activity. Typically, glucuronide derivatives possess less or no activity of the original drug, but in some cases, pharmacologically active compounds result. Morphine-6-glucuronide is a phase II metabolite of morphine with significant analgesic activity. As with the CYP enzymes, inducers, and inhibitors of phase II, enzymes exist and may influence the efficacy of drugs that rely on conjugation before excretion.

The first-pass effect is a feature of hepatic metabolism that also plays a role in the elimination of multiple drugs. Here, the enteric consumed drugs are exposed directly to the liver via the portal vein, where they undergo biotransformation before entering the systemic circulation. This activity reduces the bioavailability and needs to be factored into the dose administered to the patient. Intravenously administered drugs are not subject to the first-pass effect.

Extrahepatic drug metabolism takes place in the GI tract, kidneys, lungs, plasma, and skin.

Renal excretion completes the process of elimination that begins in the liver. Polar drugs or their metabolites get filtered in the kidneys and typically do not undergo reabsorption. They subsequently get excreted in the urine. Urinary pH has a significant impact on excretion, as drug ionization changes depending on the alkaline or acidic environment. Increased excretion occurs with weakly acidic drugs in basic urine and weakly basic drugs in acidic urine.

Excretion in the bile is another significant form of drug elimination. The liver can actively secrete ionized drugs with a molecular weight greater than 300 g/mol into bile, from where they reach the digestive tract and are either eliminated in feces or reabsorbed as part of the enterohepatic cycle.

Other pathways of excretion include the lungs, breast milk, sweat, saliva, and tears

Mobile/On-Site Drug Testing

If you're an employer needing to test 25 or more employees and looking to save time and money, we offer mobile on-site drug testing where we come to you. Call us today for more information.

Washington Laws on Drugs

Washington state enforces stringent regulations concerning controlled substances, focusing on distribution and possession of drugs like heroin and methamphetamine. Penalties include fines and imprisonment, with severity contingent on the crime’s nature and circumstances.

Controlled substances are categorized into different schedules, with Schedule I drugs deemed the most dangerous with no accepted medical use. The law mandates drug-free zones, with enhanced penalties for violations near schools or public parks.

Washington Laws on Marijuana

Recreational marijuana was legalized in Washington in 2012, permitting adults aged 21 and over to possess up to one ounce. However, public consumption remains illegal, with penalties applied for violations.

While marijuana businesses are regulated by the Washington State Liquor and Cannabis Board, strict guidelines govern the cultivation, distribution, and sale of cannabis products to ensure safety and public health standards are upheld.

Washington Drug Resources

Washington Drug Take Back Program
Dispose of unused medications safely.

WA LNI Employer Resources
Compliance resources for Washington employers.

Evergreen Treatment Services
Opioid addiction treatment and recovery services.

StopOverdose.org
Information and resources to prevent overdoses.

WA Attorney General's Opioid Initiative
Efforts to tackle opioid misuse and effects.

Drug Free Washington
Prevention initiatives and educational resources.

WA HCA Employment Services
Support for behavioral health and employment.

Youth Today Counseling
Resources for youth drug counseling in WA.

Seattle's LEAD Program
Pioneering drug-related oversight initiative.

Drug Testing Near , WA

Frequently Asked Questions

Customer Reviews